Evotec SE
0IRF.IL
International Order Book5.06
EUR
-0.05
- -
Evotec SE
0IRF.IL
(International Order Book)
Recent
price
5.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Evotec SE (EVT: Xetra) operates as a drug discovery and development partner for pharmaceutical and biotechnology companies, academic institutions, and healthcare stakeholders worldwide. The company provides integrated solutions across the R&D value chain, including target identification, hit identification, lead generation, preclinical development, and clinical support; its offerings encompass small molecules, biologics, cell therapies, and associated modalities supported by proprietary platforms such as Molecular Patient Databases, PanOmics, iPSC-based disease modeling, and AI-driven innovation; Just – Evotec Biologics delivers biologics design, development, upstream and downstream manufacturing, analytical and formulation services, and continuous manufacturing technology (J.POD); Cyprotex specializes in ADME-Tox solutions via in vitro and in silico services; additional services include data science solutions, high-throughput screening, biophysics, in vitro and in vivo pharmacology, biomarker discovery, antibody discovery, and contract research manufacturing. Evotec focuses on key therapeutic areas of oncology, cardiovascular and metabolic diseases, neurology, immunology, and protein degradation, maintaining a portfolio of over 100 proprietary or co-owned R&D assets and partnering with all Top 20 Pharma companies and more than 800 biotechs through flexible models ranging from standalone services to fully integrated programs and long-term alliances. Founded in 1993 and headquartered at Essener Bogen 7 in Hamburg, Germany, Evotec employs over 4,800 experts across sites in Europe and the United States. In November 2025, Evotec signed a landmark transaction with Sandoz AG, under which Sandoz agreed to acquire 100% of Just – Evotec Biologics EU SAS in Toulouse, France, plus an indefinite license to Evotec's continuous manufacturing platform technology for approximately US$350 million in upfront cash, more than US$300 million in license fees and milestones, and royalties on up to 10 biosimilars targeting over US$90 billion in originator sales; the deal, expected to close in Q4 2025 subject to regulatory approvals including French FDI clearance, supports an asset-lighter model, enhances margins, and confirms 2025 guidance of €760-800 million in revenues and €30-50 million adjusted EBITDA alongside an unchanged 2028 outlook of 8-12% revenue CAGR and over 20% EBITDA margin.